Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | PPIA | P62937 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10208753 | 0.84 | MAPT (0.53) | MAOBMEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL23796824 | 0.79 | MEN1 (0.60) | MAOBPPIAMEN1HSP90AA1KMT2A | |
| SCHEMBL340937 | 0.79 | HTT (0.69) | PPIAMEN1HSP90AA1KMT2ATSHR | |
| SCHEMBL10221334 | 0.79 | MAOB (0.44) | MAOBMEN1KMT2ATSHRKDM4E | |
| SCHEMBL19331053 | 0.79 | KMT2A (0.45) | MAOBPPIAMEN1HSP90AA1KMT2A | |
| SCHEMBL15934472 | 0.78 | MAOB (0.53) | MAOBPPIAMEN1HSP90AA1KMT2A | |
| SCHEMBL19334690 | 0.77 | MAOB (0.52) | MAOBPPIAMEN1HSP90AA1KMT2A | |
| SCHEMBL23796432 | 0.76 | MEN1 (0.56) | MAOBPPIAMEN1HSP90AA1KMT2A | |
| SCHEMBL15934631 | 0.76 | MAOB (0.51) | MAOBPPIAMEN1HSP90AA1KMT2A | |
| SCHEMBL20893271 | 0.75 | MAOB (0.48) | MAOBPPIAMEN1HSP90AA1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066361-A1 | 5,6,7,7a-Tetrahydrocyclopenta[f]pyrido[1,2-h][1,7] naphthyridin-11(4bH)-one Compounds and Methods of use Use (as amended) | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-02-27 | — | — | US | disclosed |
| US-12221444-B2 | 5,6,7,7a-tetrahydrocyclopenta[f]pyrido[1,2-h][1,7]naphthyridin-11(4bH)-one compounds and methods of use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-02-11 | — | — | US | disclosed |
| CN-116942663-A | Compounds for the treatment of HBV | 葛兰素史克知识产权开发有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-111433206-B | Compounds of formula (I) | 葛兰素史克知识产权开发有限公司 | 2023-07-07 | — | — | CN | disclosed |
| EP-4180431-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2023-05-17 | — | — | EP | disclosed |
| EP-4180431-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2023-05-17 | — | — | EP | disclosed |
| EP-3692040-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-12-28 | — | — | EP | disclosed |
| EP-3692040-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-12-28 | — | — | EP | disclosed |
| US-20220144834-A1 | Chemical Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-05-12 | — | — | US | disclosed |
| US-20220144834-A1 | Chemical Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-05-12 | — | — | US | disclosed |
| US-20200255428-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-08-13 | — | — | US | disclosed |
| US-20200255428-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-08-13 | — | — | US | disclosed |
| EP-3692040-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-08-12 | — | — | EP | disclosed |
| CN-111433206-A | Compound (I) | 葛兰素史克知识产权开发有限公司 | 2020-07-17 | — | — | CN | disclosed |
| WO-2019069293-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-04-11 | — | — | WO | disclosed |
| WO-2019069293-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12221444-B2 | 5,6,7,7a-tetrahydrocyclopenta[f]pyrido[1,2-h][1,7]naphthyridin-11(4bH)-one compounds and methods of use | HAVCR2, HBS1L, HBG1 | MAOB 852/4885PPIA 1288/4885MEN1 1991/4885 |
| US-20250066361-A1 | 5,6,7,7a-Tetrahydrocyclopenta[f]pyrido[1,2-h][1,7] naphthyridin-11(4bH)-one Compounds and Methods of use Use (as amended) | HAVCR2, HMBS, HBS1L | MAOB 503/4885PPIA 1402/4885MEN1 2235/4885 |
| US-20220144834-A1 | Chemical Compounds | HAVCR2, HBS1L, HLA-B | MAOB 916/4885PPIA 2377/4885MEN1 2244/4885 |
| US-20200255428-A1 | CHEMICAL COMPOUNDS | HAVCR2, HBS1L, HLA-B | MAOB 916/4885PPIA 2377/4885MEN1 2244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.